Lonza Group AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lonza Group AG
US FDA 'resilience' report charts how inspection backlog grew and impacted approvals and compliance follow-up.
Public Company Edition: Roivant’s deal sets its market cap at $7.3bn. Beyond the Werewolf and Vaccitech offerings, more drug developers are slated to go public during the first week of May. And in follow-on offerings, COMPASS Pathways raises $144m and Aldeyra brings in $125m.
Moderna, GSK and Bharat Biotech point to technology transfer, material shortages and manufacturing expertise as factors constraining COVID-19 vaccine supplies, rather than intellectual property rights. Meanwhile, Moderna's CEO forecasts a surplus of these vaccines by 2022.
While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.
- Contract Research Organization-CRO
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Drug Discovery Tools
- Other Names / Subsidiaries
- Algonomics NV
- Capsugel S.A.
- HansaBioMed Life Sciences OÜ
- InterHealth Nutraceuticals, Inc.
- Lonza Group Ltd.
- MODA Technology
- Micro-Macinazione S.A.
- PharmaCell B.V.